Literature DB >> 9266736

Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.

M Zappia1, R Colao, R Montesanti, M Rizzo, U Aguglia, A Gambardella, R L Oliveri, A Quattrone.   

Abstract

The long-duration response (LDR) to chronic levodopa treatment may mask the short-duration response (SDR) to a single dose of the drug in Parkinson's disease (PD). As a result, the measurement of SDR may be inaccurate for establishing levodopa dosing regimen in individual patients. To evaluate the possible contamination of SDR by LDR, we investigated in 16 patients with PD the characteristics of SDR to a single dose of levodopa administered after a prolonged washout from chronic therapy and after a 15-day treatment period with levodopa. Levodopa treatment produced a sustained LDR, and the SDR, measured on the 15th day of treatment, had lower magnitude and shorter duration than the response recorded after washout. Moreover, after treatment, SDR did not vary between patients with mild and severe PD, whereas, after washout, severely affected patients had larger but shorter SDR than mildly affected patients. The evaluation of SDR without the interference of LDR is critical in defining the characteristics of the therapeutic response to levodopa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266736     DOI: 10.1002/ana.410420217

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

2.  Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease.

Authors:  Gaetano Barbagallo; Maria Eugenia Caligiuri; Gennarina Arabia; Andrea Cherubini; Angela Lupo; Rita Nisticò; Maria Salsone; Fabiana Novellino; Maurizio Morelli; Giuseppe Lucio Cascini; Domenico Galea; Aldo Quattrone
Journal:  Hum Brain Mapp       Date:  2017-06-20       Impact factor: 5.038

Review 3.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

Review 4.  The role of the long-duration response to levodopa in Parkinson's disease.

Authors:  Mario Zappia; Alessandra Nicoletti
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

Review 5.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

7.  High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.

Authors:  Emilie Lacombe; Carole Carcenac; Sabrina Boulet; Claude Feuerstein; Anne Bertrand; Annie Poupard; Marc Savasta
Journal:  Eur J Neurosci       Date:  2007-09-06       Impact factor: 3.386

Review 8.  Optimising levodopa therapy.

Authors:  Giovanni Abbruzzese
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

9.  Touchscreen typing-pattern analysis for detecting fine motor skills decline in early-stage Parkinson's disease.

Authors:  Dimitrios Iakovakis; Stelios Hadjidimitriou; Vasileios Charisis; Sevasti Bostantzopoulou; Zoe Katsarou; Leontios J Hadjileontiadis
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

10.  COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.

Authors:  Angelo Antonini; Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Marco Onofrj; Mario Zappia; Aldo Quattrone
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.